511256-36-3

Basic information

• Product Name: (S)-N-Methyl-1-[3,5-bis(trifluoromethyl)phenyl]ethylamine
• Synonyms: (S)-1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-N-METHYLETHANAMINE;(S)-N-METHYL-1-[BIS-3,5-(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE;S-NME-MBT-PEM;(S)-N-Methyl-1-[3,5-bis(trifluoromethyl)phenyl]ethylamine;(1S)-1-[3,5-Bis(trifluoromethyl)phenyl]-N-methylethanamine
• CAS NO: 511256-36-3
• Molecular Formula: C₁₁H₁₁F₆N
• Molecular Weight: 271.2
• Product Categories: API intermediates
• Mol File: 511256-36-3.mol

Chemical Properties

• Boiling Point: 172.879 °C at 760 mmHg
• Flash Point: 58.356 °C
• Appearance: /
• Density: 1.259 g/cm³
• Vapor Pressure: 1.302mmHg at 25°C
• Refractive Index: 1.416
• PKA: 8.93±0.10(Predicted)
• CAS DataBase Reference: (S)-N-Methyl-1-[3,5-bis(trifluoromethyl)phenyl]ethylamine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-Methyl-1-[3,5-bis(trifluoromethyl)phenyl]ethylamine(511256-36-3)
• EPA Substance Registry System: (S)-N-Methyl-1-[3,5-bis(trifluoromethyl)phenyl]ethylamine(511256-36-3)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 511256-36-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-N-Methyl-1-[3,5-bis(trifluoromethyl)phenyl]ethylamine is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the creation of enantiomerically pure substances. These pure substances are essential in drug development, ensuring the desired therapeutic effects and minimizing potential side effects associated with less specific compounds.
Used in Organic Chemistry:
In the field of organic chemistry, (S)-N-Methyl-1-[3,5-bis(trifluoromethyl)phenyl]ethylamine serves as a valuable intermediate due to its unique chemical properties. The presence of trifluoromethyl groups on the phenyl ring allows for a variety of chemical reactions and processes, making it a versatile building block for the synthesis of complex organic compounds.

InChI:InChI=1/C11H11F6N/c1-6(18-2)7-3-8(10(12,13)14)5-9(4-7)11(15,16)17/h3-6,18H,1-2H3/t6-/m0/s1

Upstream product

• 511256-31-8 [(S)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-methyl-((S)-1-phenyl-ethyl)-amine 
• 30071-93-3 3,5-bis(trifluoromethyl)phenyl methyl ketone 
• 672906-98-8 [1-(3,5-Bis-trifluoromethyl-phenyl)-eth-(E)-ylidene]-((S)-1-phenyl-ethyl)-amine 
• 384824-41-3 [(S)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-((S)-1-phenyl-ethyl)-amine 
• 290297-43-7 3,5-bis(trifluoromethyl)-α-methyl-N-methylbenzylamine 
• 737786-85-5 1-(3,5-bis(trifluoromethyl)phenyl)ethyl methanesulfonate 
• 74-89-5 methylamine 
• 1333317-69-3 N-(1-(3,5-bis(trifluoromethyl) phenyl)ethylidene)methanamine 
• 401-95-6 3,5-Bis(trifluoromethyl)benzaldehyde 
• 1453070-36-4 (R)-N-((S)-1-(3,5-bis(trifluoromethyl)phenyl)ethyl)-2-methylpropane-2-sulfinamide 
• 1453070-37-5 (R)-N-((S)-1-(3,5-bis(trifluoromethyl)phenyl)ethyl)-N,2-dimethylpropane-2-sulfinamide 

Downstream Products

• 414910-07-9 2-(R)-(4-fluoro-2-methyl-phenyl)-4-oxo-piperidine-1-carboxylic acid [1-(S)-(3,5-bis-trifluoromethyl-phenyl)ethyl]-methylamide 
• 645379-59-5 1,1-dimethylethyl-4-[3-[{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}(methyl)amino]-1-(4-fluorophenyl)-3-oxopropylidene]-1-piperidinecarboxylate 
• 645378-54-7 1,1-dimethylethyl-4-[3-[{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}(methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-1-piperidinecarboxylate 
• 645378-73-0 1,1-dimethylethyl-4-[3-[{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}(methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-4-fluoro-1-piperidinecarboxylate 
• 645378-75-2 1,1-dimethylethyl-4-[3-[{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}(methyl)amino]-1-(4-fluorophenyl)-3-oxopropyl]-4-fluoro-1-piperidinecarboxylate 
• 644982-31-0 4-({[1-(S)-1-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-carbamoyl}-methyl)-4-(4-fluoro-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 644982-38-7 4-({[1-(S)-1-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-carbamoyl}-methyl)-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester 
• 815630-06-9 2-o-tolyl-pyrrolidine-1-carboxylic acid [1-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide 
• 870860-83-6 [(S)-1-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-carbamic acid (1R,2S)-2-phenyl-3-aza-bicyclo[3.1.0]hex-1-yl ester 
• 870861-37-3 ((1S,2R,5R)-3-{[1-((S)-3,5-Bis-trifluoromethyl-phenyl)-ethyl]-methyl-carbamoyl}-2-phenyl-3-aza-bicyclo[3.1.0]hex-1-yl)-methyl-carbamic acid tert-butyl ester 
• 870861-36-2 ((1R,2S,5S)-3-{[1-((S)-3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-carbamoyl}-2-phenyl-3-aza-bicyclo[3.1.0]hex-1-yl)-methyl-carbamic acid tert-butyl ester 
• 870860-57-4 (1S,2S)-1-hydroxy-2-phenyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid [(S)-1-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide 
• 870860-58-5 (1R,2S)-1-hydroxy-2-phenyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid [(S)-1-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide 
• 334477-19-9 2-(S)-(4-fluoro-2-methylphenyl)-3-oxopiperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide 

Relevant articles and documents

NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS

The present invention relates to a compound according to formula (A) wherein n is 1 or 2; R1 and R2 are independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, CD3 or halogen; R3 is hydrogen, C(=O)OR7 or C1-4 alkyl optionally substituted with hyd

CATALYST COMPOUNDS

The present invention relates to compounds, particularly but not exclusively, compounds for use as catalysts, methods for producing said compounds and the use of said compounds as catalysts in catalytic processes including, but not limited to, the asymmetric reduction of imine and enamine compounds and/or the reductive amination of ketone compounds. The compounds have the formula 1 wherein: R1, R2, R3, R4 and R5 are each separately selected from the group consisting of hydrogen, alkyl and aryl; X is oxygen or sulfur; W is selected from the group consisting of – OR18,–SR18, –NR19R20, –PR19R20 where R18 is alkyl or aryl, and R19 and R20 are each separately selected from the group consisting of hydrogen, alkyl and aryl; and Z has the formula 2 wherein: R6 and R7 are each separately selected from the group consisting of hydrogen, alkoxy, nitro, halogen, alkyl and aryl, or R6 and R7 are linked to form a cyclic group; and Y is oxygen, sulfur or NR10 in which R10 is selected from the group consisting of hydrogen, alkyl and aryl.

CATALYST COMPOSITIONS AND THEIR USE IN THE DE-ENRICHMENT OF ENANTIOMERICALLY ENRICHED SUBSTRATES

There is provided a process for the de-enrichment of enantiomerically enriched compositions which comprises reacting an enantiomerically enriched composition comprising at least a first enantiomer or diastereomer of a substrate comprising a carbon-heteroatom bond, wherein the carbon is a chiral centre and the heteroatom is a group V heteroatom, in the presence of a catalyst system and optionally a reaction promoter to give a product composition comprising first and second enantiomers or diastereomers of the substrate having a carbon-heteroatom bond, the ratio of second to first enantiomer or disatereomer in the product composition being greater than the ratio of second to first enantiomer or disatereomer in the enantiomerically enriched composition. Preferred catalyst systems include transition metal halide complex of the formula MnXpYr wherein M is a transition metal; X is a halide; Y is a neutral optionally substituted hydrocarbyl complexing group, a neutral optionally substituted perhalogenated hydrocarbyl complexing group, or an optionally substituted cyclopentadienyl complexing group; and n, p and r are integers. The reaction promoter is preferably a halide salt.

NK1 ANTAGONIST

The invention is to a compound exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising same and a method of treatment for neurokinin-meditated conditions.Formula (I)

OPTICALLY ACTIVE 1-(FLUORO-,TRIFLUOROMETHYL-OR TRIFLUOROMETHOXY-SUBSTITUTED PHENYL)ALKYLAMINE N-MONOALKYL DERIVATIVES AND PROCESS FOR PRODUCING SAME

An optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy-substituted phenyl)alkylamine N-monoalkyl derivative represented by the formula [4] is produced by a process including (a) reacting an optically active secondary amine, represented by th

Highly regioselective hydrogenolysis of bis(α-methylbenzyl)amine derivatives affected by the trifluoromethyl substituent on the aromatic ring

(Matrix presented) The highly regioselective hydrogenolysis of bis(α-methylbenzyl)amine derivatives proceeded with influence not from the electronic effect but from the steric effect of the trifluoromethyl substituent on the aromatic ring to provide a practical asymmetric synthesis of trifluoromethyl-substituted α-phenylethylamines.